QIAGEN NV (QGEN)

27.86
0.63 2.20
NYSE : Health Technology
Prev Close 28.49
Open 28.12
Day Low/High 27.78 / 28.25
52 Wk Low/High 25.04 / 41.55
Volume 749.19K
Avg Volume 1.30M
Exchange NYSE
Shares Outstanding 226.97M
Market Cap 6.40B
EPS 0.80
P/E Ratio 34.37
Div & Yield N.A. (N.A)

Latest News

QIAGEN Launches New QIAseq FastSelect Solutions To Accelerate RNA-seq

QIAGEN Launches New QIAseq FastSelect Solutions To Accelerate RNA-seq

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of innovative new technologies for faster, simpler library preparation for next-generation sequencing (NGS) in the growing field of RNA research.

QGEN LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors Of Its Investigation Of Qiagen N.V.

QGEN LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors Of Its Investigation Of Qiagen N.V.

NEW YORK, Oct. 9, 2019 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Qiagen N.

QGEN SHAREHOLDER ALERT: Hagens Berman Notifies Investors In Qiagen (QGEN) Of An Investigation Involving Possible Securities Law Violations

QGEN SHAREHOLDER ALERT: Hagens Berman Notifies Investors In Qiagen (QGEN) Of An Investigation Involving Possible Securities Law Violations

Class-action law firm urges QGEN investors who have suffered significant losses to learn their shareholder rights

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Investigation Of Securities Claims Against QIAGEN N.V. - QGEN

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Investigation Of Securities Claims Against QIAGEN N.V. - QGEN

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Qiagen N.

Jim Cramer: A Terrible Moment for the Stock Market

Jim Cramer: A Terrible Moment for the Stock Market

If your goal is to ratchet up trade tension? There couldn't been a better moment, hence one of the worst moments for the stock market since the trade battle began.

SHAREHOLDER ALERT: Gardy & Notis, LLP Investigation Of Shareholder Claims Against Qiagen (NYSE: QGEN)

SHAREHOLDER ALERT: Gardy & Notis, LLP Investigation Of Shareholder Claims Against Qiagen (NYSE: QGEN)

NEW YORK, Oct. 8, 2019 /PRNewswire/ -- The law firm Gardy & Notis, LLP is investigating potential claims against Qiagen N.

Qiagen Tumbles on Sales Warning, CEO Departure

Qiagen Tumbles on Sales Warning, CEO Departure

Shares of Qiagen slide after the company warns its third-quarter sales will be lower than expected and that its CEO is resigning.

QIAGEN Announces CEO Leadership Transition

QIAGEN Announces CEO Leadership Transition

QIAGEN N.V.

QIAGEN And Illumina Partner To Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

QIAGEN And Illumina Partner To Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.

Illumina And QIAGEN Partner To Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Illumina And QIAGEN Partner To Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.

QIAGEN Launches Enhanced GeneGlobe Design & Analysis Hub, Combining Curated Knowledge, Content-based Assays And Analyses For Life Science Research

QIAGEN Launches Enhanced GeneGlobe Design & Analysis Hub, Combining Curated Knowledge, Content-based Assays And Analyses For Life Science Research

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its newly enhanced GeneGlobe Design & Analysis Hub, bringing next-level experiment planning, execution and follow-up to life science researchers.

QIAGEN Announces Change In Global Sales Structure

QIAGEN Announces Change In Global Sales Structure

QIAGEN N.V.

QIAGEN's New QIAstat-Dx Gastrointestinal Panel Demonstrates Excellent Performance In Multicenter Clinical Study In Europe

QIAGEN's New QIAstat-Dx Gastrointestinal Panel Demonstrates Excellent Performance In Multicenter Clinical Study In Europe

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the publication of a multicenter clinical study demonstrating the accuracy of its QIAstat-Dx syndromic testing solution for diagnosing the causes of acute gastroenteritis.

QIAGEN Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed And Interpreted

QIAGEN Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed And Interpreted

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QIAGEN Clinical Insight (QCI®), its clinical decision support platform for interpretation and reporting of variants derived from analysis of next-generation sequencing (NGS) data, has...

QIAGEN And McKesson Agree To Distribute QIAstat-Dx Syndromic Testing Solution To Smaller Hospitals And Other Select Segments In The United States

QIAGEN And McKesson Agree To Distribute QIAstat-Dx Syndromic Testing Solution To Smaller Hospitals And Other Select Segments In The United States

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an agreement for McKesson Medical-Surgical Inc.

QIAGEN To Deliver Genomic Insights For Japan's New Molecular Oncology Clinical Research And Precision Medicine Initiative

QIAGEN To Deliver Genomic Insights For Japan's New Molecular Oncology Clinical Research And Precision Medicine Initiative

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAGEN Clinical Insight (QCI) offering was selected by the National Cancer Center of Japan, as part of the Japan's Ministry of Health, Labour and Welfare's precision medicine...

QIAGEN And DiaSorin Collaborate On Novel QuantiFERON-based Test With Breakthrough Potential For Earlier Detection Of Lyme Disease

QIAGEN And DiaSorin Collaborate On Novel QuantiFERON-based Test With Breakthrough Potential For Earlier Detection Of Lyme Disease

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the expansion of their QuantiFERON collaboration to develop an ultra-sensitive diagnostic test for Lyme disease, which is expected to address a significant...

QIAGEN Launches First FDA-approved Companion Diagnostic For PIK3CA Biomarkers To Enhance Precision Medicine In Breast Cancer

QIAGEN Launches First FDA-approved Companion Diagnostic For PIK3CA Biomarkers To Enhance Precision Medicine In Breast Cancer

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the immediate launch of its therascreen ® PIK3CA RGQ PCR Kit ( therascreen PIK3CA Kit) after it received U.

Inovio And QIAGEN Establish Collaboration To Develop Diagnostic Test For VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Inovio And QIAGEN Establish Collaboration To Develop Diagnostic Test For VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio's VGX-3100

TheStreet Quant Rating: B- (Buy)